American Hemp Protection Act of 2025

The American Hemp Protection Act of 2025 (HR6209) directly counteracts the FY2026 agriculture appropriations act (P.L. 119-37), which reimposed federal controls on certain hemp products effective November 12, 2026. This bill, if passed, ensures that hemp and hemp-derived products with less than 0.3% delta-9 THC remain excluded from the Controlled Substances Act, maintaining their legal status established by the 2018 Farm Bill. This legislative move is critical for the continued growth and stability of the hemp industry, which faced a significant regulatory setback with the FY2026 appropriations act. Funding in the hemp industry primarily flows through consumer spending on products such as CBD, delta-8 THC, and other cannabinoid-infused goods. Companies involved in cultivation, processing, and retail distribution of these products are positioned to capture this market. The repeal of stricter federal controls prevents a contraction of the legal market, allowing these companies to continue their operations and expansion plans without the burden of reclassification as Schedule I controlled substances. This bill protects existing revenue streams and allows for further innovation in the hemp-derived product space. Historically, the passage of the 2018 Farm Bill, which legalized hemp, led to a significant boom in the nascent cannabis and CBD markets. Following its enactment, companies like Tilray Brands ($TLRY) and Canopy Growth ($CGC) saw increased investor interest and market capitalization, reflecting the expanded legal market. While direct stock price movements immediately after the 2018 Farm Bill are complex due to broader cannabis market dynamics, the overall sentiment for companies involved in hemp cultivation and processing was overwhelmingly positive, leading to new market entrants and substantial capital investment. Conversely, the FY2026 appropriations act created uncertainty and downward pressure on these stocks, which HR6209 aims to reverse. Specific winners from the passage of HR6209 include major cannabis and hemp-focused companies such as Tilray Brands ($TLRY), Canopy Growth ($CGC), Sundial Growers ($SNDL), GrowGeneration ($GRWG), and Scotts Miracle-Gro ($SMG). These companies either directly produce hemp-derived products, provide cultivation supplies, or operate in the broader cannabis ecosystem that benefits from a clear and expansive legal hemp market. The bill prevents a significant loss of market share and revenue that would have occurred under the FY2026 appropriations act. There are no direct losers from this bill's passage, as it restores the status quo favorable to the hemp industry. The bill has been referred to the House Committee on Agriculture. The next step involves committee hearings and potential markups. Given that Representative Mace, a Republican, is the sponsor and there are three cosponsors, the bill has initial legislative momentum. The timeline for passage through committee and a floor vote is uncertain but will likely accelerate as the effective date of the FY2026 appropriations act (November 12, 2026) approaches. Investors should monitor committee progress and any statements from key committee members.